Aegerion Pharmaceuticals Earnings Preview: Can This Streak Finally End?

Aegerion Pharmaceuticals (NASDAQ:AEGR) will report earnings before markets open on Tuesday, April 30th. Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company researches small-molecule therapeutics for cardiovascular and metabolic desease. Aegerion’s product candidates limit secretion of cholesterol and triglycerides.

Here is your Cheat Sheet to Aegerion Pharmaceuticals Earnings:

Earnings Expectations: Analysts expect earnings of $-0.72 per share on revenues of $570.00K.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.6 to a loss $0.67. For the current year, the average estimate is a loss of $2.42, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Aegerion Pharmaceuticals has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 0.00 0.00 0.00 0.00 0.00
Diluted EPS ($) -9.35 -5.07 -2.03 -2.64

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 0.00 0.00 0.00 0.00 0.00
Diluted EPS ($) -0.6562 -0.55 -0.63 -0.59 -0.8571

Past Performance:
Aegerion Pharmaceuticals has missed analyst estimates 4 times in the past four quarters. Shareholders could expect a bust if the company misses estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]